Cancer Treatment Reviews
Volume 27, Issue 5 , Pages 289-294 , October 2001

Defining a future role for radiogenic therapy

  • J.M. Kaminski

      Affiliations

    • Department of Radiology, Medical College of Georgia, Augusta, USA
    • ,
  • R.J. Kaminski

      Affiliations

    • Department of Radiology, Medical College of Georgia, Augusta, USA
    • ,
  • A.P. Dicker

      Affiliations

    • Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, USA
    • ,
  • J.L.C. Urbain

      Affiliations

    • Department of Nuclear Medicine, Cleveland Clinic Foundation, Ohio, USA

References 

  1. Weiden PL, Breitz HB, Press O. Pretargeted Radioimmunotherapy (PRIT) or treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000;15:15–29
  2. O'Donnell RT, DeNardo GL, Kukis DL. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for Non-Hodgkin's Lymphoma. J Nucl Med. 1999;40:2014–2020
  3. Foss FM, Raubitscheck A, Mulshine JL. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res. 1998;4:2691–2700
  4. LeMaistre CF, Saleh MN, Kuzel TM. Phase I trial of a ligand fusion-protein (DAB389IL2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998;91:399–405
  5. Joensuu H, Roberts PJ, Sarlomo-Rikala M. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. NEJM. 2001;344:1052–1056
  6. Hahnfeldt P, Panigrahy D, Volkman J. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, tumor response, and post vascular dormancy. Cancer Res. 1999;59:4770–4775
  7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med. 1995;1:27–31
  8. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmac Ther. 1994;63:265–311
  9. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931–10934
  10. Folkman J. Angiogenesis and its inhibitors. In:  Devita VT,  Helman S,  Rosenberg SA editor. Important Advances in Oncology. Philadelphia: JB Lippincott; 1985;p. 42–62
  11. DeVore R, Fehrenbachter L, Herbst R. A randomized phase III trial comparing RHUMAB VEG (Recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol. 2000;19:485a
  12. Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999;27:655–666
  13. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther. 1991;49:239–268
  14. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem. 1985;260:9720–9726
  15. Jolivet J, Schilsky RL, Bailey BD, Drake JC, Chabner BA. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cells. J Clin Invest. 1982;70:351–360
  16. Hall EJ. Chemotherapeutic agents from the perspective of the radiation biologist. Radiobiology for the Radiobiologist. Philadelphia: Lippincott Williams and Wilkins; 2000; p. 470–494
  17. McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med. 2000;44:88–95
  18. Marian G, Bodei L, Adelstein SJ, Kassis AI. Emerging roles for radiometabolic therapy of tumors based on auger electron emission. J Nucl Med. 2000;41:1519–1521
  19. Janson ET, Westlin JE, Ohrvall U, Oberg K, Lukinius A. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors. J Nucl Med. 2000;41:1514–1518
  20. Kassis AI, Adelstein SJ, Haydock C, Sastry KS, McElvany KD, Welch MJ. Lethality of Auger electron from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res. 1982;90:363–373
  21. Woo DV, Li D, Mattis JA, Steplewski Z. Selective chromosomal damage and cytotoxicity of 125I-labeled monoclonal antibody 17-1A in human cancer cells. Cancer Res. 1989;49:2952–2958
  22. Makrigiorgos GM, Kassis AI, Baranowska-Kortylewicz J. Radiotoxicity of 5-[123I]iodo-2′-deoxyuridine. Radiat Res. 1989;118:532–544
  23. Kassis AI, Sastry K SR, Adelstein SJ. Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: implications of localized energy deposition of Auger processes. Radiat Res. 1987;109:78–89
  24. Chan PC, Lisco E, Lisco H, Adelstein SJ. The radiotoxicity of iodine-125 in mammalian cells. II. A comparative study on cell survival and cytogenetic responses to 125IUdR, 131IudR, and 3HTdR. Radiat Res. 1976;67:332–343
  25. Hofer KG, Harris CR, Smith JM. Radiotoxicity of intracellular 67Ga, 125I, and 3H: nuclear versus cytoplasmic radiation effects in murine L1210 leukemia. Int J Radiat Biol. 1975;28:225–241
  26. Kassis AI, Adelstein SJ, Mariana G. Radiolabeled nucleoside analogs in cancer diagnosis and therapy. Q J Nucl Med. 1996;40:301–319
  27. Kassis AI, Adelstein SJ. Preclinical animal studies with radiodeoxyuridine. J Nucl Med. 1996;37:10S–12S
  28. Welt S, Divgi CR, Kemeny N. Phase I/II study of iodine-125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1996;14:1787–1797
  29. Meredith RF, Khazaeli MB, Plotl WE. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med. 1995;36:2229–2233
  30. Snelling L, Miyamoto CT, Bender H. Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma. 1995;14:111–114
  31. Brady LW, Miyamoto C, Woo DV. Malignant astrocytoma treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys. 1992;22:225–230
  32. Sisson JC, Shapiro B, Hutchinson RJ. Treatment of neuroblastoma with [125I]metaiodobenzylguanidine. J Nucl Biol Med. 1991;35:255–259
  33. Tiensuu Janson E, Eriksson B, Oberg K. Treatment with high dose (111In-DTPA-D-PHE1)-octrotide in patients with neuroendocrine tumors: evaluation of therapeutic and toxic effects. Acta Oncol. 1999;38:373–377
  34. McCarthy KE, Woltering EA, Espenan GD, Cronin M, Maloney TJ, Anthony LB. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am. 1998;4:94–102
  35. Krenning EP, Kooij PP, Pauwels S. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion. 1996;57:57–61
  36. Fjalling M, Andersson P, Forsell-Aronsson E. Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med. 1996;37:1519–1521
  37. Krenning EP, Kooij PP, Bakker WH. Radiotherapy with a radiolabeled somatostatin analogue (111In-DTPA-D-Phe1)-octreotide: a case history. Ann NY Acad Sci. 1994;733:496–506
  38. McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In-pentetreotide. Q J Nucl Med. 2000;44:88–95
  39. McLean JR, Blakey DH, Douglas GR, Bayley J. The Auger electron dosimetry of indium-111 in mammalian cells in vitro. Radiat Res. 1989;119:205–218
  40. Kairemo JA, Tenhune M, Jekunen AP. Gene therapy using antisense oligodeoxynucleotides labeled with Auger-emitting radionucleotides. Cancer Gene Ther. 1998;5:408–412
  41. Karamychev VN, Panyutin IG, Kin M. DNA cleavage by 111In-labeled oligodeoxynucleotides. J Nucl Med. 1999;41:1093–1101
  42. Panyutin IG, Neumann RD. Sequence-specific DNA double-strand breaks induced by triplex-forming oligonucleotides. Nucleic Acids Res. 1994;22:4879–4982
  43. Sahu SK, Wen PY, Foulon CF. Intrathecal 5-[125I]iodo-2′-deoxyuridine in a rat model of leptomeningeal metastasis. J Nucl Med. 1997;38:386–390
  44. Mairs RJ, Wideman CL, Angerson WJ. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model. Br J Cancer. 2000;82:74–80
  45. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379:458–460
  46. Spitzweg C, Zhang S, Bergert ER. Prostate-specific antigen (PSA) promoter-driven androgen inducible expression of sodium iodide symporterin prostate cancer cell line. Cancer Res. 1999;59:2136–2141
  47. Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 1999;59:661–668
  48. Boland A, Ricard M, Opolon P. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res. 2000;60:3484–3492
  49. Cho JY, Xing S, Liu X. Expression and activity of human Na+/I-symporter in human glioma cells by adenovirus-mediated gene therapy. Gene Ther. 2000;7:740–749
  50. Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 1999;59:661–668
  51. Chung T DK, Mauceri HJ, Hallahan DE. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 1998;5:344–349
  52. Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T. Transgene gene expression in malignant glioma using a replication-defective adenoviral vector containing the EGR-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoyuridine. Human Gene Ther. 1998;9:1409–1417
  53. Hallahan DE, Mauceri HJ, Seung LP. Spatial and temporal control of gene therapy using ionizing radiation. Nature Med. 1995;1:786–791
  54. Advani SJ, Chmura SJ, Weichselbaum RR. Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumor. Semin Oncol. 1997;24:633–638
  55. Kassis AI, Wen PY, Van de Abbeele AD. 5-[125I]iodo-2′-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med. 1998;39:1148–1154
  56. Perou CM, Sorlie T, Elsen MB. Molecular portraits of human breast tumors. Nature. 2000;406:747–752
  57. Alizadeh AA, Eisen MB, Davis RE. Distinct types of diffuse larger B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  58. Gasparini G, Calabria R, Gion M. Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints. Cancer J. 2000;6:117–131

PII: S0305-7372(01)90236-1

doi: 10.1053/ctrv.2001.0236

Cancer Treatment Reviews
Volume 27, Issue 5 , Pages 289-294 , October 2001

Article Tools